Minnie Fang earned her Ph.D in Biomedical Engineering at Huazhong University of Science and Technology. After working as a lecturer in Shanghai Jiao Tong University shortly, she did her postdoctoral research at the Max Delbruck Center for Molecular Medicine in Berlin, Germany. Then she worked in the German Rheumatism Research Center Berlin (DRFZ), Germany as a research scientist. She joined Lilly China in 2015 and now is the Research IT Leader in China. Dr. Fang has 15 years experiences in bioinformatics and genomics research. She and her team focus on data mining of omics data in preclinical and early clinical studies in Oncology and Metabolic diseases.
Data Mining and Cloud Computing Accelerate Drug Discovery
Traditional drug discovery is a complex years to decades process with a high degree of uncertainty. The challenges are lack of the knowledge of disease mechanism, biomarkers, patient heterogeneity, target mechanism of action (MOA) etc. Emerging technologies such as genomics filled many of those gaps and therefore became standard approaches in both preclinical research and clinical development. Next-generation sequencing is the most widely used technology for understanding genetic information. However, the explosion of data raises the challenges in data storage, process and most importantly, how to mine and interpret the data. Here we show some business cases of the application of big data and cloud computing in target identification and validation.